APA (7th ed.) Citation

Mokgokong, R., Cislo, P., Tudone, E., Weinstein, E., & Cappelleri, J. C. (2025). Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial. Infectious Diseases & Therapy, 14(12), 2763. https://doi.org/10.1007/s40121-025-01228-w

Chicago Style (17th ed.) Citation

Mokgokong, Ruth, Paul Cislo, Elena Tudone, Edward Weinstein, and Joseph C. Cappelleri. "Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial." Infectious Diseases & Therapy 14, no. 12 (2025): 2763. https://doi.org/10.1007/s40121-025-01228-w.

MLA (9th ed.) Citation

Mokgokong, Ruth, et al. "Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial." Infectious Diseases & Therapy, vol. 14, no. 12, 2025, p. 2763, https://doi.org/10.1007/s40121-025-01228-w.